BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuo MH, Tseng CW, Lee CH, Tseng KC. Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C. Tzu Chi Med J 2020;32:331-8. [PMID: 33163377 DOI: 10.4103/tcmj.tcmj_247_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
2 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
3 Kuo MH, Tseng C, Lee C, Yang Y, Wu H, Lin H, Chu Y, Chen Y, Tseng K. Identification and management of contraindicated drug–drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. Journal of the Formosan Medical Association 2021. [DOI: 10.1016/j.jfma.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]